A German CML-Study IV randomized >1000 patients into three cohorts: (1) imatinib monotherapy 400 mg QD, (2) imatinib 400 mg QD plus IFN-α, and (3) imatinib 800 mg QD. Here, IFNA2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.